Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Robert Devenyi, MD, FRCSC, FACS

Robert Devenyi, MD, FRCSC, FACS, Professor and Chief of Ophthalmology, University of TorontoProfessor and Chief of Ophthalmology
University of Toronto
Member of the Healthcare Council

Robert Devenyi, MD, MBA, FRCSC, FACS, is a Professor of Ophthalmology and Vision Sciences at The University of Toronto, Canada. He is the Director of the Donald K. Johnson Eye Center, Director of Retinal Services at University Health Network and Ophthalmologist-in-Chief at the University Health Network, The University of Toronto. He is also the Team Ophthalmologist for The Toronto Maple Leafs. He has experience in all aspects of adult and pediatric vitreoretinal surgery, anti-VEGF agents, and rheopheresis, and has also been a consultant in this field. Dr. Devenyi is also a member of the Clinical Studies Resource Centre of Toronto Western Research Institute. His research focuses on the development of a novel treatment for neovascular age-related macular degeneration, involving ultra high speed indocyanine angiography and a coupled diode laser, the surgical repair of complex retinal detachments, diabetic retinopathy, and all aspects of macular degeneration. (This is me - Update Profile)


Employment History
2001 - present Professor and Chief of Ophthalmology
University of Toronto
1993 - present Director of Retinal Services
University Health Network

GLG Study Groups with Robert Devenyi, MD, FRCSC, FACS(?)

Study Group Name Members
Ophthalmologists 1529

GLG NewsSM Analyses by Robert Devenyi, MD, FRCSC, FACS(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
It is morally reprehensible that the NEI was forced to act and create the CATT trial | 03-11-2008
Author: Robert Devenyi, MD, FRCSC, FACS, Professor and Chief of Ophthalmology, University of Toronto

I agree...the present situation is really quite absurd...in most practices...IF a third party is willing to pay for Lucentis...patients usually get Lucentis...if patients have to pay themselves...they usually receive Avastin...despite there not being a shred of convincing evidence that Lucentis is superior...

Genentech enrages vitreoretinal specialists | 12-06-2007
Author: Robert Devenyi, MD, FRCSC, FACS, Professor and Chief of Ophthalmology, University of Toronto

-Retinal community unites against Genentech -both the American Association of Ophthalmology and the American Society of Retinal Specialists have condemned Genentech's actions -this represents profit-driven pharma at their worst -very poor decision by Genentech...not only to galvanize the profession...

Genentech has a huge problem with their credibility | 02-15-2007
Analysis of: Dear Doctor Letter regarding Lucentis | www.gene.com
Author: Robert Devenyi, MD, FRCSC, FACS, Professor and Chief of Ophthalmology, University of Toronto

Genentech should have voluntarily compared Lucentis with Avastin.All of Genentech's efforts to promote Lucentis seem self serving and insincere.

GLG InstituteSM Seminars with Robert Devenyi, MD, FRCSC, FACS(?)

 
Robert Devenyi, MD, FRCSC, FACS has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Robert Devenyi, MD, FRCSC, FACS









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-04T09:45:15.927